Share

June 12, 2012; 78 (24) Editorials

Multiple sclerosis or multiple possibilities

The continuing problem of misdiagnosis

Richard A. Rudick, Aaron E. Miller
First published May 11, 2012, DOI: https://doi.org/10.1212/WNL.0b013e318259e2e2
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
595

Share

Article Information

vol. 78 no. 24 1904-1906
DOI: 
https://doi.org/10.1212/WNL.0b013e318259e2e2
PubMed: 
22581931
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published May 11, 2012.

Article Versions

Copyright & Usage: 
Copyright © 2012 by AAN Enterprises, Inc.

Author Disclosures

    1. Richard A. Rudick, MD and
    2. Aaron E. Miller, MD
  1. Richard A. Rudick, MD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Speaking Engagement, Biogen Idec, 2010; Investigator Meeting, Biogen Idec, 2010

    Editorial Boards:

    1. Editorial Board, Lancet Neurology 2008-present Editorial Board, Neurotherapeutics, 2010-present

    Patents:

    1. Biomarker for interferon response in multiple sclerosis. Patent pending

    Publishing Royalties:

    1. Multiple Sclerosis Therapeutics, Third Edition, Cohen, JA, Rudick RA (Eds). Informa Healthcare, UK, 2007

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Biogen Idec Consultation x 2, 2011; x 1, 2012 Wyeth/Pfizer Pharmaceuticals, Consultation 2011 Genzyme Consultation 2011 Novartis Consultation 2011

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biomarkers for the therapeutic response to IFNb. Measuring gene expression before and after IFNb injections in 85 patients (original study sponsored by NIH - PO1NS38667 - current extension of that study sponsored by Biogen Idec).

    Research Support, Government Entities:

    1. NIH - PO1NS38667 (2004-2009)Director, Project 4 NIH - UL1RR024989 (2007-2011)Co-Principal Investigator NIH - KL2RR024990 (2007-2011) Principal Investigator

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society, Research Program Advisory Committee (Chairman) American Society for Experimental Neurotherapeutics (Member, Board of Directors)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Aaron E. Miller, MD
    3. Scientific Advisory Boards:

    1. Sanofi-aventis, Biogen Idec, GlaxoSmithKline, EMD Serono, Teva Neuroscience; Daiichi-Sankyo, Merck Serono, Novartis, ONO, Acorda

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. sanofi-aventis--travel expenses to Paris for steering committee meeting, May 09; BiogenIdec travel expenses for scientific advisory meeting Feb 09, Jan 10; Daiichi- Sankyo travel expenses for trip to Chicago for DSMB meeting July 09; ONO travel expenses for trip to Philadelphia for DSMB meeting November 09; Acorda travel expenses to Washington to testify before FDA Advisory panel October 09

    Editorial Boards:

    1. Continuum (AAN) received fees as editor 2003-2012

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Sanofi-aventis, Biogen Idec, GlaxoSmithKline, EMD Serono, Teva Neuroscience; Daiichi-Sankyo, Merck Serono, Novartis, ONO, Acorda Speakers’ Bureaus: BiogenIdec--2009--dinner presentation EMD Serono--2009-10--Dinner presentations

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Acorda--subinvestigator 2008-10 Novartis--2008-12 Site PI and subinvestigator Genzyme 2008-2012 subinvestigator Sanofi-aventis 2009-2012 site subinvestigator BiogenIdec--2010-2012 site subinvestigator

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. I have occasionally reviewed medico-legal cases as a defense expert; the cases are not in the public domain and remain confidential

  1. From the Department of Neurology (R.A.R.), Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH; and Department of Neurology (A.E.M.), Mount Sinai School of Medicine, New York, NY.
  1. Correspondence & reprint requests to Dr. Rudick: rudickr{at}ccf.org
View Full Text

Article usage

Article usage: May 2012 to April 2022

AbstractFullPdfSource
May 2012208086Highwire
Jun 2012990207181Highwire
Jul 20121743053Highwire
Aug 201259512Highwire
Sep 201252716Highwire
Oct 201232710Highwire
Nov 2012074Highwire
Dec 2012032Highwire
Jan 2013057Highwire
Feb 201302821Highwire
Mar 201301615Highwire
Apr 2013095Highwire
May 2013057Highwire
Jun 20131356Highwire
Jul 20132821Highwire
Aug 2013922Highwire
Sep 20132533Highwire
Oct 201342710Highwire
Nov 20132632Highwire
Dec 20136634Highwire
Jan 20143654Highwire
Feb 20141331Highwire
Mar 20143235Highwire
Apr 20142544Highwire
May 20142054Highwire
Jun 20141375Highwire
Jul 20141561Highwire
Aug 20141131Highwire
Sep 20141163Highwire
Oct 2014882Highwire
Nov 2014555Highwire
Dec 20141814Highwire
Jan 20151352Highwire
Feb 20151014Highwire
Mar 20153720Highwire
Apr 20152010Highwire
May 20151821Highwire
Jun 201530144Highwire
Jul 20153121Highwire
Aug 20152311Highwire
Sep 20152043Highwire
Oct 20151910Highwire
Nov 20152433Highwire
Dec 20152622Highwire
Jan 20161820Highwire
Feb 20161242Highwire
Mar 20161611Highwire
Apr 20163142Highwire
May 2016614Highwire
Jun 20161310Highwire
Jul 20161165Highwire
Aug 20162312Highwire
Sep 20161032Highwire
Oct 20161402Highwire
Nov 20162213Highwire
Dec 20161334Highwire
Jan 20171213Highwire
Feb 20171734Highwire
Mar 2017522Highwire
Apr 2017400Highwire
May 2017822Highwire
Jun 2017410Highwire
Jul 20171121Highwire
Aug 2017311Highwire
Sep 20171011Highwire
Oct 20171422Highwire
Nov 20171121Highwire
Dec 20171123Highwire
Jan 20182610Highwire
Feb 20181921Highwire
Mar 20182987Highwire
Apr 20183841Highwire
May 20183131Highwire
Jun 20184200Highwire
Jul 20185110Highwire
Aug 20182912Highwire
Sep 20184520Highwire
Oct 20185911Highwire
Nov 20183923Highwire
Dec 20182001Highwire
Jan 20191804Highwire
Feb 20193033Highwire
Mar 20191600Highwire
Apr 20191911Highwire
May 20193300Highwire
Jun 20191911Highwire
Jul 20191334Highwire
Aug 20191431Highwire
Sep 20191210Highwire
Oct 20192400Highwire
Nov 20193020Highwire
Dec 2019601Highwire
Jan 20201521Highwire
Feb 20201610Highwire
Mar 2020820Highwire
Apr 2020710Highwire
May 20201710Highwire
Jun 20202601Highwire
Jul 20201800Highwire
Aug 20201100Highwire
Sep 2020631Highwire
Oct 20202800Highwire
Nov 20201921Highwire
Dec 20201920Highwire
Jan 20212721Highwire
Feb 20214221Highwire
Mar 20212200Highwire
Apr 20212810Highwire
May 20211531Highwire
Jun 20212410Highwire
Jul 20211230Highwire
Aug 20212420Highwire
Sep 20211110Highwire
Oct 20212220Highwire
Nov 20212611Highwire
Dec 2021500Highwire
Jan 20221000Highwire
Feb 20221800Highwire
Mar 20222001Highwire
Apr 20221120Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me